2011
DOI: 10.1111/j.1478-3231.2011.02650.x
|View full text |Cite
|
Sign up to set email alerts
|

Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia

Abstract: Rifaximin improves cirrhosis-related thrombocytopenia and this could be related with the reduction of endotoxaemia.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
29
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 48 publications
(31 citation statements)
references
References 46 publications
2
29
0
Order By: Relevance
“…Because endotoxin is a main stimulus of IL‐6 production in cirrhotic patients, these therapies may influence the production and circulating levels of IL‐6. Indeed, it has been recently demonstrated that rifaximin significantly decreases circulating levels of endotoxin and IL‐6 in patients with alcoholic cirrhosis 26 . In the cirrhotic patients without MHE, there is no correlation between serum levels of IL‐6 and plasma levels of ammonia, and IL‐6 levels of some patients without MHE are close to those of patients with MHE.…”
Section: Discussionmentioning
confidence: 99%
“…Because endotoxin is a main stimulus of IL‐6 production in cirrhotic patients, these therapies may influence the production and circulating levels of IL‐6. Indeed, it has been recently demonstrated that rifaximin significantly decreases circulating levels of endotoxin and IL‐6 in patients with alcoholic cirrhosis 26 . In the cirrhotic patients without MHE, there is no correlation between serum levels of IL‐6 and plasma levels of ammonia, and IL‐6 levels of some patients without MHE are close to those of patients with MHE.…”
Section: Discussionmentioning
confidence: 99%
“…Rifaximin is a nonabsorbable oral antibiotic derived from rifamycin that has been used to treat hepatic encephalopathy, traveler's diarrhea, and irritable bowel syndrome [23]. The intestinal absorption of rifaximin is only 0.007%, which prevents it from exerting systemic or adverse effects.…”
Section: Introductionmentioning
confidence: 99%
“…Rifaximin has been shown to improve thrombocytopenia (a marker of portal hypertension) and MELD in alcoholic cirrhosis through the reduction of endotoxemia 53 . Probiotics have been shown to improve neutrophil function, cytokine response, and liver function.…”
Section: Current Therapies and Future Approachesmentioning
confidence: 99%